The latest report by IMARC Group, titled “Diabetes Drugs and Diagnostics Market Report by Segment (Oral Antidiabetics, Insulin, Diabetes Diagnostics), and Region 2024-2032“, The global diabetes drugs and diagnostics market size reached US$ 74.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 134.0 Billion by 2032, exhibiting a growth rate (CAGR) of 6.8% during 2024-2032.

Factors Affecting the Growth of Diabetes Drugs and Diagnostics Industry:

• Rising Diabetes Prevalence and Awareness:

The global diabetes drugs and diagnostics market is experiencing significant growth due to the alarming rise in diabetes prevalence worldwide. Diabetes has reached epidemic proportions, with millions of individuals diagnosed each year. This consumer is primarily attributed to unhealthy lifestyles, including sedentary behavior and poor dietary choices. Moreover, increased awareness about the importance of early diabetes detection and management has led to higher demand for diagnostics tools and medications. This factor is driving market growth as pharmaceutical companies and diagnostic device manufacturers strive to meet this growing demand. It also emphasizes the need for continuous research and development to introduce innovative products for effective diabetes management.

• Advancements in Diagnostic Technologies:

Another driving force behind the global diabetes drugs and diagnostics market is the continuous advancement in diagnostic technologies. The development of more accurate, rapid, and user-friendly glucose monitoring devices, such as continuous glucose monitors (CGMs) and flash glucose monitoring systems, has transformed diabetes management. These innovations provide real-time data to patients and healthcare professionals, enabling better glycemic control. Additionally, the integration of artificial intelligence (AI) and machine learning in diabetes diagnostics has enhanced predictive capabilities, leading to early intervention and personalized treatment plans. These technological advancements improve patient outcomes and also create opportunities for companies to expand their product portfolios, thus boosting market growth.

• Growing Investment in Research and Development:

Investment in research and development (R&D) plays a crucial role in driving the diabetes drugs and diagnostics market. Pharmaceutical companies and diagnostic device manufacturers are dedicating substantial resources to develop novel drug therapies and diagnostic tools. The focus is on improving treatment efficacy and patient convenience. This includes the development of insulin analogs, oral antidiabetic drugs, and minimally invasive diagnostic devices. Government initiatives and funding support for diabetes-related R&D further accelerate innovation in the field. As companies continue to invest in cutting-edge technologies and explore new treatment modalities, the market is expected to witness sustained growth.

Competitive Landscape with Key Player:

• Abbott Laboratories
• AstraZeneca plc
• B. Braun Medical Ltd.
• Dexcom, Inc
• Eli Lilly and Company
• Insulet Corporation
• Janssen Pharmaceuticals Inc. (Johnson & Johnson)
• LifeScan IP Holdings, LLC
• Medtronic plc
• Merck & Co. Inc.
• Novo Nordisk A/S
• Roche Diabetes Care, Inc (F. Hoffmann-La Roche AG)
• Sanofi-Aventis U.S. LLC (Sanofi S.A.)

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/diabetes-drugs-diagnostics-market/requestsample

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Segment:

• Oral Antidiabetics
  • Breakup by Class
    • Biguanides
    • Alpha-Glucosidase Inhibitors
    • Sodium-Glucose Cotransport -2 Inhibitors (SGLT-2 Inhibitors)
    • Dipeptidyl Peptidase-4 Inhibitors (DPP-4 Inhibitors)
    • Sulfonylureas
    • Dopamine -D2 Receptor Agonist
    • Others

• Insulin
  • Breakup by Class
    • Long Acting Insulin
    • Fast Acting Insulin
    • Short Acting
    • Others
• Diabetes Diagnostics
  • Breakup by Product Type
    • Blood Glucose Meters
    • Blood Glucose Strips
    • Lancets
  • Breakup by End-User
    • Hospitals and Clinics
    • Home Healthcare
    • Ambulatory Care Centers
    • Others

Based on the segment, the market has been divided into, oral antidiabetics (breakup by class (Biguanides, Alpha-Glucosidase Inhibitors, Sodium-Glucose Cotransport -2 Inhibitors (SGLT-2 Inhibitors), Dipeptidyl Peptidase-4 Inhibitors (DPP-4 Inhibitors), Sulfonylureas, Dopamine -D2 Receptor Agonist, Others)), insulin (breakup by class (Long Acting Insulin, Fast Acting Insulin, Short Acting, Others)),  Diabetes Diagnostics (Breakup by Product Type (Blood Glucose Meter, Blood Glucose Strips, Lancets) Breakup by End-User (Hospitals and Clinics, Home Healthcare, Ambulatory Care Centers, Others).

Market Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America’s dominance in the market is attributed to its high healthcare spending, a significant prevalence of diabetes, and a robust healthcare infrastructure that supports the demand for diabetes drugs and diagnostics.

Global Diabetes Drugs and Diagnostics Market Trends:

The aging population and rapid urbanization are significant drivers of the diabetes market. Aging individuals are more prone to diabetes, and as the global population ages, the demand for diabetes management solutions increases. Moreover, urbanization often leads to sedentary lifestyles and unhealthy dietary habits, further contributing to the rise in diabetes cases. This demographic shift creates a sustained market demand for diabetes drugs and diagnostics. Additionally, changes in healthcare policies and increased insurance coverage for diabetes-related services have a positive impact on the market. Many governments and healthcare systems worldwide have recognized the economic burden of diabetes and have taken steps to improve access to diabetes medications and diagnostic tools. This enhanced coverage encourages individuals to seek early diagnosis and treatment, thereby driving market growth.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high- quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163